HEALTH-RELATED QUALITY OF LIFE WITH USTEKINUMAB VERSUS ADALIMUMAB FOR INDUCTION AND MAINTENANCE THERAPY IN BIOLOGIC-NAÏVE PATIENTS WITH MODERATE-TO-SEVERE CROHN'S DISEASE: PROMIS-29 IN THE SEAVUE STUDY

Matthieu Allez  ¹     James D. Lewis  ²     Timothy Hoops  ³     Tony Ma  ³     Zhijie Ding  ³     Erik Muser  ³     Christopher Gasink  ³     Remo Panaccione  ⁴     Edward V. Loftus Jr  ⁵     Silvio Danese  ⁶     Bruce E. Sands  ⁷     Peter Irving  ⁸     James Izanec  ^8    
1 Université de Paris, Paris, France
² Perelman School of Medicine at the University of Pennsylvania, Philadelphia, United States
³ Janssen Scientific Affairs, LLC, Horsham, United States
⁴ University of Calgary, Calgary, Canada
⁵ Mayo Clinic College of Medicine, Rochester, United States
⁶ Humanitas Clinical and Research Center, Humanitas University, Milan, Italy
⁷ Icahn School of Medicine at Mount Sinai, New York, United States
⁸ Guy’s and Saint Thomas’ Hospitals NHS Trust, London, United Kingdom

Topic
IBD, Immunology

Session
IBD: Clinical trials III

Conference
UEG Week Virtual 2021

Citation
United European Gastroenterology Journal 2021; 9 (Supplement 8)